Alnylam Pharmaceuticals Inc (ALNY) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Total Revenue Chart for Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY) revenue for FY2025 was USD 3.7B, a 65.2% change from FY2024. Alnylam Pharmaceuticals Inc's revenue grew from USD 176.0K in 2003 to USD 3.7B in 2025 (2110091.5% over 22 years). Earnings per share moved from USD -1.04 in 2010 to USD -9.30 in 2022. Revenue compound annual growth rate: 5-year CAGR of 49.8%, 10-year CAGR of 56.9%, 20-year CAGR of 38.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$31.65B
Implied Share Price
$236.56
Enterprise Value
$29.94B
Revenue (TTM)
$4.80B
EBITDA
$1.05B
Profit Margin
16.13%
Trailing P/E
41.65
Forward P/E
27.55
Price/Book (MRQ)
23.62
Price/Sales (TTM)
6.59
EV/EBITDA
27.09
EV/Revenue
6.23
Dividend Yield
—
Book Value
$10.12
Free Cash Flow (FY2025)
$465.38M
Free Cash Flow Yield
1.47%

Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.